RE: Expectations18 Feb 2023 15:38
Here are my expectations:
Science Day to include presentation of the data emerging from the phase 1a clinical trial of AVA6000.
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will host a Science Day for City analysts and fund managers on 23rd February 2023 to discuss recent progress within the Company's Therapeutics Division and hear from selected key opinion leaders in the field of oncology.
The event will include an update on the ongoing preclinical programmes as well as on progress in the ALS-6000-101 phase 1a clinical trial of AVA6000, Avacta's lead pre|CISIONTM tumour targeted chemotherapeutic, a modified form of the chemotherapy doxorubicin.